VYVANSE: payments to doctors
Payments that named VYVANSE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.4M
- Providers
- 33,740
- Transactions
- 112,909
- Average per transaction
- $21
The per-transaction average — $21 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 33,740 providers the average total is $71, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,926,809 | 80.3% |
| Shire North American Group Inc | $472,945 | 19.7% |